Ranbaxy Wins U.S. Approval to Sell Generic of Pfizer’s Lipitor

Ranbaxy Laboratories Ltd. (RBXY), India’s biggest drugmaker, won U.S. clearance to sell a generic version of Pfizer Inc. (PFE)’s $10.7 billion Lipitor cholesterol pill.

The Food and Drug Administration approved Ranbaxy’s copy of the world’s top-selling drug, which will be manufactured by Ohm Laboratories in New Brunswick, New Jersey, the agency said today in a statement. Watson Pharmaceuticals Inc. (WPI) today began selling a copy of Lipitor in the U.S. under an agreement with New York- based Pfizer. Watson’s version didn’t require FDA clearance because Pfizer is providing the drug to sell without the brand label in return for a share of the revenue.

To contact the reporter on this story: Molly Peterson in Washington at mpeterson9@bloomberg.net

To contact the editor responsible for this story: Adriel Bettelheim at abettelheim@bloomberg.net

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.